Development of 3DMPUS as a Decision Support Tool for Patients With Liver Tumors Undergoing Therapy
Trial ID or NCT#
Status
NOT RECRUITING
Purpose
This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3D-MPUS is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biomarkers.
Official Title
Development of 3DMPUS as a Decision Support Tool for Patients With Liver Tumors Undergoing Therapy
Eligibility Criteria
- 1. The participant is about to undergo a new course of therapy for primary or metastatic liver cancer. 2. The participant is age > 18 years. 3. Participant has at least one target lesion (≥1cm and <14cm) 4. The participant is willing to comply with protocol requirements. 5. The participant has the ability to understand and the willingness to sign a written informed consent document.
- 1. Participant has documented anaphylactic or other severe reactions to any ultrasound or CT contrast media. 2. Participant has documented severe Hypersensitivity to macrogol/ polyethylene glycol (PEG). 3. Participant has documented the presence of a cardiac shunt or pulmonary hypertension (pulmonary artery pressure >90 mmHg). 4. Participant has documented renal insufficiency with a creatinine level of >1.5mg/dl. 5. Participant has documented uncontrolled systemic hypertension. 6. Participant has documented concomitant diseases like acute endocarditis, prosthetic valve, hyperactive coagulation states and/ or recent thromboembolism, and sepsis 7. Participant is pregnant (positive urine or serum beta-hCG) or lactating.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
David Marcellus, BS
650-723-4547
View on ClinicalTrials.gov
